Efficacy and safety of lower-dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicenter, randomized, noninferiority trial.

Introduction: Reduced doses of antiretroviral (ARV) drugs may lower toxicity while preserving efficacy. We aimed to evaluate the efficacy of reduced doses of both tenofovir disoproxil fumarate (TDF) and efavirenz compared with standard doses for the treatment of HIV-1 infection in antiretroviral-naive adults.Methods: In this open-label, non-inferiority trial, HIV-1-infected antiretroviral-naive adults from 3 centers in China were randomly assigned to receive either a lower dose anti-retroviral regimen comprised of TDF (200 mg), efavirenz (400 mg), and standard dose lamivudine (300 mg) or the standard dose regimen. The primary endpoint was the proportion of participants with HIV-1 RNA